Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalaprilat Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalaprilat Anhydrous SCHEMBL18033873 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL2406720 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL37289 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL3090322 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL11204535 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL6106603 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8149345 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL21046169 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL37288 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885LMNA 2026/4885SMN1; SMN2 540/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885LMNA 2061/4885SMN1; SMN2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.